1. Home
  2. XXII vs GRI Comparison

XXII vs GRI Comparison

Compare XXII & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

HOLD

Current Price

$0.54

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.05

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXII
GRI
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.6M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
XXII
GRI
Price
$0.54
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
1.3M
29.9K
Earning Date
05-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
69.96
N/A
EPS
N/A
N/A
Revenue
$25,832,530.00
N/A
Revenue This Year
$370.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.18
52 Week High
$11.37
$6.70

Technical Indicators

Market Signals
Indicator
XXII
GRI
Relative Strength Index (RSI) 22.08 40.00
Support Level $0.51 $1.97
Resistance Level $1.15 $2.23
Average True Range (ATR) 0.08 0.11
MACD 0.06 -0.01
Stochastic Oscillator 12.14 33.33

Price Performance

Historical Comparison
XXII
GRI

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: